Weight Loss Drugs Explained

What are GLP-1 drugs — and why is everyone talking about them?
Tennis legend Serena Williams recently admitted to using a GLP-1 medication. Did her openness help reduce the stigma — or add more pressure around weight loss?

From celebrities to Wall Street, medications like Ozempic, Wegovy, and Mounjaro are reshaping weight loss. But what are the pros and cons — and are they really safe?

In this video, I ask Dr. Resham Uttamchandani — Double Board-Certified in Family & Obesity Medicine — your top questions and concerns.

Chapters:
0:00 Serena Williams announcement
1:10 Poll on your thoughts about Serena
2:18 GLP-1 drugs market & trends
3:59 What is obesity medicine
6:11 What are GLP-1s
8:10 What's insulin resistance
9:05 Who qualifies for them
10:27 The Cost
13:15 Who shouldn’t use them
13:55 Key side effects
14:40 Serious complications
15:15 Questions to ask
16:57 Muscle loss & mitigation
18:00 Weight gain without them
19:02 How long to take them
20:00 Long-term effects
20:05 Behavioral challenges
23:00 Ethics& Access
.
CONTACT Dr. Resham Uttamchandani
*Instagram: @dr.resham.uttamchandani (  / dr.resham.uttamchandani  )
*Website: https://elevateubydoctoru.com/

#GLP1 #Ozempic #Wegovy #zebound #mounjaro #WeightLoss #serenawilliams #diet #health
==================
SUBSCRIBE here, if you don't want to miss a video:    / @leonelakhani  
.
. Instagram: ADD   / itsleone  
.
. TikTok: ADD   / leonelakhani  

================
Sources for this video:

Serena Williams on the Today Show -    • Serena Williams on Why She Chose to Use GL...  
https://www.eonline.com/news/1421462/...

RO PRESS RELEASE:
https://ro.co/press/serena-williams/
Williams’ husband is an investor in Ro and serves on its board.

IQVIA
https://www.iqvia.com/library/article...

In 2020, global spending on anti-obesity medications (AOMs) stood at approximately US$3 billion. By 2024, that figure had soared to US$30+ billion - a more than  tenfold increase in just four years. Given the current trend and the pace of innovation in the disease area, the market is expected to sustain its explosive growth well into the future. Between 2024 and 2034, the global AOM market is expected to grow at a CAGR of 13–15% and the total market size is expected to reach  approximately US$130 billion. Biologics are leading the way in the obesity drug market, with GLP-1 and GIP receptor agonists holding the major share. However, non-biologics are expected to regain some market share in the forecast period as the market diversifies and new treatment options emerge.
https://www.iqvia.com/locations/emea/...

ELI LILLY
Eli Lilly — US/Rest of the World page. 8 — https://investor.lilly.com/static-fil...

ELI LILLY INTERNATIONAL EXPANSION - https://www.reuters.com/business/heal...

https://www.reuters.com/business/heal...

https://www.prnewswire.com/news-relea...

NOVO NORDISK
https://www.novonordisk.com/content/d...

CHINA — GENERIC DRUG
https://www.pharmaceutical-technology...

https://www.reuters.com/business/heal...